

INNODIA

Symposium on T1D Therapies

September 28th, 2026
Milan



EASD 2026

28 September
02 October

Milan
Italy

#EASD2026
easd.org



EVENT information

WHAT to expect

A full afternoon dedicated to the most promising advances in Type 1 Diabetes research and therapeutics. The Symposium will bring together medicine developers focused on therapies for people with T1D, offering a fast-paced, high-impact overview of treatments with the potential to change the course of the disease.

WHY join

Be where breakthroughs begin.

Leading voices in research, biotech, and clinical care will unveil what's next in T1D – and how we can get there faster, together, and with greater impact. A unique chance to connect, be inspired, and shape the future of T1D.

WHO should attend

Open to all curious minds: whether you're a researcher, clinician, innovator, investor, funder, or a person living with T1D. If you're eager to stay ahead of the curve in diagnosis, screening, and life-changing treatment innovation - and enjoy some easy-going, purposeful networking - **this is for you!**

HOW to join

Attendance is free. Spaces are limited.

Registration and all information are managed via [myINNODIA App](#)*.

WHEN & WHERE it happens

14:30 – 15:00 Registration

 [EASD Venue](#) - [Milan Allianz MiCo – Convention Centre](#)

15:00 – 19:00

Symposium on T1D Therapies - Berlin Hall South Wing

Open to all — no EASD registration required

- attendees registered for EASD can collect their badge at the Entrance Area
- not registered attendees can collect a guest badge at the Interplan Industry Counter

19:30–23:30

The **INNODIA Networking Dinner** - a unique opportunity to rounding off the day together over good food and conversation.

 [Istituto dei Ciechi di Milano](#) – via Vivaio, 7 - Sala Barozzi

Housed in an elegant 19th-century building in the heart of Milan, the venue is home to a charitable foundation that has supported people with visual impairment since 1840. The dinner will take place in the historic Sala Barozzi and its adjoining atrium, where a walking buffet will give you the chance to mingle and reconnect with colleagues in a uniquely warm and atmospheric setting.

We look forward to rounding off the day together over good food and conversation.

(*) How to register via the myINNODIA App

If you have not yet activated your account, please check your inbox or spam folder to locate the invitation.

Once your account is active:

1. Log in to the myINNODIA App and open the My Rooms section in the menu on the left-hand side, then click on *The Hall room*. In the room, under the *Events* tab, you will find the two events listed (Symposium and Networking Dinner).
2. Select the Attending button on the event(s) you wish to join.
3. To add the event(s) to your personal calendar, click the blue 'Add to Calendar' button on the right.
4. To check if your registration is confirmed, open the *My Events* page from the left-hand menu, and you will find a confirmation message below the event information. In the same menu, under *My Card*, you will find a **QR Code** — please have this ready at the registration desk on the day of the event.

INNODIA Symposium on T1D Therapies

15:00 - 19:00 @ Milan Allianz MiCo – Convention Centre, Berlin Hall, South Wing

15:00 – 19:00

The Symposium

This symposium will bring together **medicine developers and research accelerators focused on disease-modifying therapies for T1D**. Through a series of 6-minute pitches, the session will explore the most promising clinical approaches - from immune intervention and beta cell preservation to regeneration and cell-based therapies. A fast-paced overview of the treatments that have the potential to change the course of the disease.

15:00 Manuela Battaglia, INNODIA
Updates on INNODIA & Symposium overview

17:30 Coffee break & networking

SESSION 1: BETA CELL HEALTH

15:15 Introduction, Décio Eizirik

Ruchi Jain, **Abarceo Pharma AB**

Anath Shalev, **Tiximed, Inc**

Juan Pablo Frías, **Biomea Fusion, Inc**

Alfonso Galderisi, **Yale University**

Knut Dahl-Jørgensen, **University of Oslo**

15:55 Q&A, Décio Eizirik & Virginia Stone

SESSION 3: CELL THERAPY

18:00 Introduction, Tim Tree

Marko Repic, **GentiBio, Inc**

Piotr Trzonkowski, **PolTREG**

Paolo Fiorina, **Altheia Science**

Mathias Svahn, **NextCell Pharma**

18:25 Q&A, Tim Tree & Pierre Lemaitre

SESSION 2: IMMUNE MODULATION

16:05 Introduction, Chantal Mathieu

Henk Streefkerk, **Nimvec Therapeutics**

Melissa K. Thomas, **Eli Lilly and Company**

Tara Mahon, **IMMUNOCORE**

Alexandra Kropotova, **SAB Biotherapeutics**

Courtney Crane, **Mozart Therapeutics**

Fabien Dépis, **Treg Shield Bio**

Jan Hillson, **Zag Bio**

Teresa Quattrin, **University of Buffalo**

Sofija Andjelic & Vugar Azizov, **Sanofi**

17:10 Q&A, Chantal Mathieu & Clara Heider

SESSION 4: BETA CELL REPLACEMENT

18:35 Introduction, Eelco de Koning

Katrin Ridders, **Evotec**

Camillo Ricordi, **University of Miami**

18:50 Q&A, Eelco de Koning & Sufyan Hussain

19:00 Manuela Battaglia, INNODIA - Closure

19:30 – 23:30 **INNODIA Networking Dinner**


INNODIA Strategic Supporters

The INNODIA Symposium has been made possible thanks in part to the valuable contributions of our Strategic Supporters, each backing this initiative in line with their capacity.

This support represents both a strong endorsement of the INNODIA vision and a meaningful contribution to the growth, sustainability, and independence of the open, neutral T1D ecosystem INNODIA is building.

We thank all our Strategic Supporters for believing in this vision and for helping us move the T1D field forward, together.

To learn more about the program visit <https://www.innodia.org/strategic-support-program>.



Companies and Organizations Presenting

• Abarceo Pharma AB

Abarceo Pharma, founded in 2017 as a spin-out of the Lund University Diabetes Centre (based in Malmö, Sweden) is a preclinical-stage company targeting beta-cell dysfunction through mitochondrial health. Its founders were the first to describe that the mitochondrial protein VDAC1 becomes dysfunctional and represents a novel target in Type 2 diabetes. Abarceo's approach aims to revert beta cells from a dysfunctional to a functional state, preserving beta-cell function so that patients can produce their own insulin naturally. Preliminary data further show that deranged VDAC1 is important for inflammatory immune responses. The company is advancing small-molecule VDAC1 oligomerization inhibitors through lead optimization, alongside collaborations with Eli Lilly (anti-VDAC1 antibodies) and Biogen. The scientific work originated in type 2 diabetes, and now the company has preliminary data in T1D.

Presented by: **Ruchi Jain** (Scientific Director) www.abarceo.com

• Altheia Science

Altheia Science, founded in 2017 in Milan (Italy) is a clinical-stage company developing gene- and cell-based therapies that promote immune tolerance in autoimmune diseases. Its approach harnesses the immune-regulatory checkpoint molecule PD-L1, whose expression is reduced on blood stem cells of patients with autoimmune conditions, including type 1 diabetes. The lead program consists of a patient's own hematopoietic stem and progenitor cells, genetically engineered with a lentiviral vector to express PD-L1, being evaluated in the IMMUNOSTEM Phase I/II trial in patients with recent-onset T1D who retain residual beta-cell function.

Presented by: **Paolo Fiorina** (Co-Founder & Chief Scientific Officer) www.altheiascience.com

• Biomea Fusion, Inc.

Biomea Fusion is a California-based clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes and obesity. Its lead program, icovamenib (BMF-219), is being evaluated across multiple Phase 2 clinical studies for diabetes and is designed to preserve, restore, and potentially expand functional pancreatic beta-cell mass. The company's pipeline also includes BMF-650, an oral small-molecule GLP-1 receptor agonist being developed for obesity and other metabolic diseases.

Presented by: **Juan Pablo Frías** (Chair, Scientific Advisory Board) <https://biomeafusion.com>

• DiViD Prevention Trial

Nordic Diabetes Virus Detection and Prevention Trial

The DiViD Prevention Trial builds on evidence — from the DiViD biopsy study, the Exeter Repository and nPOD — that a low-grade, persistent enterovirus infection is present in the pancreas both at diagnosis of type 1 diabetes and in earlier prediabetic stages. This viral presence is thought to increase beta-cell stress, releasing misfolded proteins that act as neoantigens and help drive the autoimmune destruction of beta cells. In the earlier DiViD Intervention trial, antiviral treatment with pleconaril and ribavirin preserved endogenous insulin production at diagnosis. This Nordic prevention trial now asks whether the same antiviral treatment can halt the disease process much earlier, before it takes hold. The Phase 2 double-blind, randomized, placebo-controlled trial enrolls 260 children aged 3–16 with a single diabetes-related autoantibody (Pre-stage 1 T1D), across screening centers in Oslo, Oulu, Turku, the Steno Center and Lund. Participants receive six months of treatment and are followed for five years. The primary endpoint is whether antiviral therapy reduces progression to a second autoantibody — a key marker of advancing disease — with secondary measures including autoantibody reversion, progression to clinical T1D, C-peptide, glucose tolerance and enterovirus presence.

Presented by: **Knut Dahl-Jørgensen** (Professor of Pediatrics, University of Oslo)

• Eli Lilly and Company

Lilly is a medicine company turning science into healing for people around the world. We have been pioneering life-changing discoveries for over 150 years. Our clinical trials for people with Type 1 diabetes include studies with baricitinib, a small molecule selective JAK1/JAK2 inhibitor that modulates cytokine signaling involved in immune activation and inflammation. It is being studied in two Phase 3 trials for disease modification in type 1 diabetes, investigating both delay of clinical onset in high-risk individuals and preservation of beta-cell function in those with new-onset disease. Tirzepatide, an agonist of both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, is being studied in Phase 3 trials in people with Type 1 diabetes and overweight or obesity.

Presented by: **Melissa K. Thomas** (Vice President, Diabetes, Obesity, and Cardiometabolic Research) www.lilly.com

• Evotec

Evotec is a biotechnology company that develops highly effective therapeutics, both in proprietary programs and in co-creation with pharma, biotech and academic partners. Within cell therapy, it offers a fully integrated, end-to-end iPSC platform — one of the broadest in the industry — taking projects from inception to the clinic with in-house GMP manufacturing, and spanning anti-tumor, regenerative and immune-modulation cell types. In type 1 diabetes, Evotec's focus is beta-cell replacement: it produces iPSC-derived, insulin-producing beta cells in islet-like clusters as an off-the-shelf, scalable source of the cells that patients lose to autoimmune attack. This work is being advanced through a strategic partnership with Sernova, which combines Evotec's beta cells with its implantable Cell Pouch device.

Presented by: **Katrin Ridders** (Principal Scientist) www.evotec.com

• GentiBio, Inc

GentiBio, Inc. is a clinical-stage biotechnology company co-founded by pioneers in Treg biology and immunology from Seattle Children's Research Institute and Benaroya Research Institute to develop engineered regulatory T cells (eTreg) programmed to treat autoimmune and inflammatory diseases. Its platform is designed to address the key challenges faced by Treg therapies, namely tissue targeting, stability and IL-2 support — across both autologous and allogeneic approaches. Its lead candidate, GNTI-122, is a single-dose autologous eTreg therapy for recently diagnosed type 1 diabetes, engineered to migrate to the pancreas and preserve endogenous insulin production; it holds FDA Fast Track designation and entered the Phase 1 POLARIS trial in 2026.

Presented by: **Marko Repic** (Director, Pharmacology & Toxicology) www.gentibio.com

• IMMUNOCORE

A commercial-stage biotechnology company that discovered, developed and commercialized the world's first approved TCR (T-cell receptor) therapy. Using its proprietary ImmTAX platform, it develops transformative immunomodulating medicines to improve outcomes for patients with cancer, infectious diseases and autoimmune diseases. Its ImmTAA1 bispecific molecules pair an organ-specific TCR with an immunosuppressive PD-1 agonist effector. The first candidate, IMC-S118A1, is targeted specifically to pancreatic beta cells and is intended as a tissue-specific treatment for type 1 diabetes. Based on the preclinical data, the molecule will shortly enter the clinic in a Phase 1 first-in-human dose escalation trial.

Presented by: **Tara Mahon** (Principal Scientist II, Research) www.immunocore.com

• Mozart Therapeutics

Mozart Therapeutics based in Seattle (USA) is a clinical-stage company developing modulators of CD8 T regulatory cells (CD8 Tregs) for autoimmune diseases. Mozart's lead candidate, MTX-101, is a bispecific "autoimmune checkpoint inhibitor" that binds the CD8 Treg receptors KIR and CD8 to selectively activate these cells and restore their ability to eliminate pathogenic immune cells. In type 1 diabetes, MTX-101 is designed to restore CD8 Treg function so they can eliminate the pathogenic CD4 and CD8 T cells that drive destruction of insulin-producing beta cells. A Phase 1a study in healthy adults was completed in 2025 showing MTX-101 was well tolerated, and an interim analysis of the Phase 1b study has demonstrated that MTX-101 selectively activates CD8 Treg, is associated with pathogenic CD4 and CD8 T cell reduction, and extension of beta cell viability in a pancreatic organoid model. Early c-peptide data demonstrate preservation of MMTT c-peptide AUC up to 20 weeks after a single dose of MTX-101.

Presented by: **J Courtney Crane** (Senior Vice President) www.mozart-tx.com

• NextCell Pharma

NextCell Pharma, based in Sweden, is a clinical-stage cell therapy company developing NXTCL-T1D, its lead drug candidate for type 1 diabetes based on the company's patent-protected NXTCL platform. NXTCL-T1D is an allogeneic mesenchymal stromal cell (MSC) therapy derived from umbilical cord tissue. Using a proprietary selection algorithm, the therapy is designed to modulate the immune system and preserve residual beta-cell function through a single, off-the-shelf infusion. Long-term follow-up in adults with newly diagnosed type 1 diabetes has demonstrated sustained preservation of endogenous insulin production for more than six years following a single infusion. NextCell will also present topline results from the ProTrans-Young trial (n=66), evaluating NXTCL-T1D in children and adolescents with recently diagnosed type 1 diabetes.

Presented by: **Mathias Svahn** (Chief Executive Officer) www.nextcellpharma.com

• Nimvec Therapeutics

Nimvec Therapeutics B.V. is a biotechnology company established in 2025 and headquartered in Leiden, the Netherlands. The company has developed a proprietary non-immunogenic viral vector platform for transgene delivery, with a therapeutic pipeline spanning rare and prevalent diseases including monogenic disorders, autoimmune conditions, and chronic inflammatory diseases. In the autoimmune space, Nimvec is developing disease-modifying gene therapies that work by inducing antigen-specific immune tolerance. Unlike conventional gene therapies that often trigger strong immune responses preventing repeat dosing, Nimvec's platform leverages the unique properties of Simian Virus 40 (SV40) to evade immune activation during cell entry, enabling re-administration. To induce tolerance, Nimvec exploits the liver's natural tolerogenic environment. Vector-encoded self-antigens are presented by liver cells, tolerizing antigen-specific T cells while preserving the rest of the immune system intact. In preclinical models of type 1 diabetes, a single low-dose intravenous injection of the lead candidate NimvecAM510, encoding human proinsulin, protected mice from developing hyperglycemia, demonstrating its potential to restore immune tolerance and halt beta-cell destruction. In 2025 the company formalized a manufacturing agreement with NorthX Biologics to scale up production and accelerate the path toward clinical trial.

Presented by: **Henk Streefkerk** (Chief Executive Officer) www.nimvec.com

• PolTREG

A clinical-stage company focusing on cell therapy for autoimmune diseases. PolTREG is developing T-regulatory (Treg) cell-based products including polyclonal Tregs, CAR-Tregs, TCR-Tregs, antigen-specific oligoclonal Tregs and in vivo Treg-inducing technology. Currently, its clinical-stage products are autologous, but the company is also working on allogeneic modalities. All products are manufactured in its GMP facility in Gdańsk, Poland. To date, PolTREG has completed four clinical trials in type 1 diabetes (T1D) and multiple sclerosis (MS), treating more than 100 patients. In October 2024 it launched a placebo-controlled Phase 2 trial of its lead Treg product, PTG-007, in presymptomatic (Stage 1) T1D in children at high genetic risk. In March 2026, drawing on 7–12-year patient follow-up data, the European Medicines Agency's CHMP qualified PolTREG-T1D (PTG-007) for submission of a marketing-authorization application for symptomatic T1D under the EU centralized procedure — a key step toward potential commercialization.

Presented by: **Piotr Trzonkowski** (Chief Executive Officer) www.poltreg.com

• SAB Biotherapeutics

A clinical-stage biopharmaceutical company developing fully human, multi-specific immunoglobulins produced without human donors or convalescent plasma, for immune and autoimmune disorders. Its lead asset, SAB-142, is a fully human anti-thymocyte immunoglobulin (hATG) for the treatment of type 1 diabetes. It is designed to act like rabbit anti-thymocyte globulin but, being fully human, it avoids the immunogenicity that prevents rabbit ATG from being re-dosed, enabling repeat, disease-modifying dosing. In a completed Phase 1 trial, SAB-142 was well tolerated and non-immunogenic across doses, including re-dosing, with early signals of C-peptide preservation in a small cohort of adults with established T1D. It has advanced into the registrational Phase 2b SAFEGUARD trial in newly diagnosed (Stage 3) T1D, recruiting globally. SAB-142 also advanced into a Phase 3 investigator-initiated PRISE-hATG trial led by Dr. Haller in participants with Stage 3 T1D onset up to 2 years.

Presented by: **Alexandra Kropotova** (Executive Vice President & Chief Medical Officer) www.sab.bio

• SANOFI

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. At the INNODIA EASD symposium, Sanofi will present updates on the overall vision and ambition for the research pipeline in T1D. Specific focus will be on FABULINUS and Beta Preserve trials that are facilitated by INNODIA across INNODIA Clinical Trial Sites. FABULINUS is a randomized, double-blind, placebo-controlled, multi-center Phase 2b trial of frexalimab (a CD40L-antagonist monoclonal antibody) for the preservation of pancreatic β -cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy. Beta Preserve is a randomized, double-blind Phase 3 trial of teplizumab (an anti-CD3 monoclonal antibody) versus placebo in participants aged 1–25 years with recently diagnosed Stage 3 type 1 diabetes.

Presented by: **Sofija Andjelic** (Global Medical Strategy Lead Autoimmune T1D) and **Vugar Azizov** (Global Medical Lead Pipeline Autoimmune T1D) www.sanofi.com

• Tegoprubart in islet and kidney transplantation

Costimulatory blockade by a novel anti-CD40L to replace Prograf immunosuppression in islet and kidney transplantation

An update on clinical trials of tegoprubart (Eledon Pharmaceuticals) in recipients of kidney and islet transplantation in people with type 1 diabetes — collaborative trials between the University of Chicago and the University of Miami Diabetes Research Institute. The results demonstrated superior mean eGFR with tegoprubart compared with tacrolimus (Prograf), with all 12 islet transplant recipients achieving insulin independence. These findings open the way to islet transplantation in people with type 1 diabetes and chronic kidney disease.

Presented by: **Camillo Ricordi** (Professor of Surgery and Chief, University of Miami Miller School of Medicine)

• TIXiMED, Inc.

TIXiMED, founded in 2021 in Birmingham (Alabama) is a clinical-stage company developing TIX100, an oral inhibitor of TXNIP (thioredoxin-interacting protein) for type 1 diabetes. It builds on Dr Anath Shalev's research at the University of Alabama at Birmingham, which identified TXNIP's role in beta-cell loss. Unlike verapamil — a blood-pressure drug shown to lower TXNIP but with off-target effects — TIX100 targets TXNIP directly to protect beta-cell health and islet function. It could become the first oral, non-immunosuppressive, disease-modifying treatment for T1D, preserving beta-cell function across all stages of disease, with potential in type 2 diabetes and metabolic dysfunction-associated steatotic liver disease. In a completed Phase 1 trial, TIX100 was safe and well tolerated, and post-hoc analysis showed improved glucose homeostasis after a standardized meal — the first evidence of a biological effect in humans.

Presented by: **Anath Shalev** (Founder & Chief Scientific Officer) www.tiximed.com

• TregShield Bio

TregShield Bio Inc., founded in 2024 and based in Massachusetts (USA), is developing organ-specific, tissue-activated biologics for immune and inflammatory diseases. Its proprietary platform is designed so that therapies remain inactive in the circulation and switch on only within diseased tissue, aiming to deliver powerful immune modulation with an improved safety profile. Current standard of care remains largely symptomatic; this new class of therapeutic biologics is designed to reach targets and mechanisms previously limited by systemic toxicity, and to address the drivers of disease chronicity, with the aim of durable, off-treatment remission. The platform is both target-agnostic and indication-agnostic: preclinical in vivo studies across atopic dermatitis, rheumatoid arthritis, and type 1 diabetes models have demonstrated strong, more durable off-treatment efficacy with tissue-restricted target engagement and minimal systemic target engagement. The company is actively seeking partnership opportunities to advance its technology in type 1 diabetes: TRS-201, a first-in-class, pancreas-activable antibody with a dual mechanism of action: (i) neutralizing local pathogenic T cells while (ii) boosting local regulatory T cells. Atopic dermatitis is the company's current lead program, with the platform designed to extend across additional immune and inflammatory indications.

Presented by: **Fabien Dépis** (Founder, President & CEO) www.tregshield.com

• VIST1D

Verapamil in Stage 1 T1D

This talk presents the rationale for the design of VIST1D, a Phase 3 randomized controlled trial in Stage 1 T1D aiming to prevent progression to Stage 2 or Stage 3 disease. Trials in Stage 1 are challenging because of the heterogeneity within that stage, so VIST1D uses a risk-driven, deterministic escalation strategy that repurposes three drugs, each already shown individually to slow the autoimmune process in T1D. Treatment escalates through verapamil (first line), biosimilar ustekinumab (second line) and biosimilar golimumab (third line), with escalation guided by Index60 — a validated risk marker derived from glucose and C-peptide during an OGTT. The three drugs were chosen for their complementary, non-redundant targets, established safety profiles, practical oral or subcutaneous dosing, and the recent availability of biosimilars: verapamil (an L-type calcium channel blocker) has an anti-apoptotic effect on beta cells; ustekinumab acts on T cells by inhibiting IL-12/IL-23; and golimumab, an anti-TNF agent, targets innate immunity. This design keeps cost down while maximizing the safety and efficacy of the intervention.

Presented by: **Alfonso Galderisi** (Associate Professor Adjunct, Department of Pediatrics, Yale University)

• WAVE T1D Trial

WAVE T1D — a randomized Phase 1/2 trial of low-dose anti-thymocyte globulin (ATG) with subsequent adalimumab or verapamil in new-onset type 1 diabetes — is a multi-center, randomized controlled trial conducted in the U.S. and sponsored by City of Hope, designed collaboratively by leaders in the field to test whether combining therapies can offer sustained preservation of endogenous insulin production in stage 3 T1D. It builds on three FDA-approved drugs, each of which preserved insulin production as a single agent in earlier trials with an acceptable safety profile. All participants first receive two low-dose ATG infusions to dampen islet autoimmunity, followed by randomization to two years of adalimumab, verapamil, or placebo — agents that may protect beta cells and reduce inflammation. The trial enrolls people aged 9 to under 21 with stage 3 T1D within six months of diagnosis. The primary endpoint is preservation of insulin secretion (stimulated C-peptide AUC on mixed-meal tolerance testing), with metabolic and safety measures assessed through two years and treatment extended to three, to test for durable benefit.

Presented by: **Teresa Quattrin** (Distinguished Professor of Pediatrics, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo)

• Zag Bio

Founded by Diane Mathis (Harvard Medical School), Alan Crane (Polaris Partners), Jo Viney (Seismic Therapeutics) and John Kulman, Zag Bio is a preclinical-stage biotech developing systemically administered biologics that direct the uptake of self-antigens by thymic antigen-presenting cells (APCs). Its platform uses proprietary thymic multiomic datasets to identify APC-specific uptake receptors and route target self-antigens to them, inducing potent, durable antigen-specific thymic regulatory T cells (tTregs). By co-opting the body's own mechanism for establishing central immune tolerance, Zag Bio aims to transform outcomes in autoimmunity, with an initial focus on type 1 diabetes. The company emerged from stealth in 2025 with backing from AbbVie, Regeneron and Sanofi, and is advancing its lead T1D program toward a first-in-human study.

Presented by: **Jan Hillson** (Chief Medical Officer) www.zagbio.com